169 episodes
CCO Oncology Podcast Clinical Care Options
-
- Education
-
-
4.9 • 8 Ratings
-
Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Clinical Care Options. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.
-
Applying the Latest Evidence and NCCN Guideline Recommendations in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Listen in as Danielle M. Brander, MD; Deborah Stephens, DO; and Brian Hill, MD, PhD, discuss key aspects of the CLL guidelines from the NCCN and share strategies for applying these recommendations in your clinical practice to optimize treatment and outcomes.
-
Homologous Recombination Repair (HRR) Testing and Targeted Therapy in Prostate Cancer
Listen to this podcast featuring a multidisciplinary discussion between Colin C. Pritchard, MD, PhD, a pathologist, and Heather H. Cheng, MD, PhD, a medical oncologist, for expert guidance on optimal biomarker testing to guide treatment decisions in advanced prostate cancer.
-
Real-world Perspectives on Novel HER2-Targeted and TROP-2–Directed Therapies in Advanced Breast Cancer
Discussion between experts on novel and emerging HER2-targeted and TROP-2–directed therapies for patients with HER2-low, hormone receptor–positive, and triple-negative advanced breast cancer.
-
Current Considerations for Adverse Event Management With HER3-Directed Agents
In this podcast, Rebecca S. Heist, MD, MPH, discusses the safety profile and management of potential adverse events associated with HER3-directed therapies in lung cancer.
-
Unpacking the Potential of HER3-Targeted Therapy in NSCLC
In this podcast, Helena Yu, MD, and Rebecca S. Heist, MD, MPH, discuss ongoing clinical trials of HER3-targeted therapy for patients with advanced NSCLC and how these agents have the potential to change treatment options in this setting.
-
Recent Advances in ADCs and Rationale for HER3 as a Target in Lung Cancer
In this podcast, Helena Yu, MD, discusses recent advances in the field of antibody–drug conjugates and the current rationale for targeting HER3 for treatment of non-small-cell lung cancer.